



October 30, 2024

Company name:	SanBio Co., Ltd. (Code: 4592 TSE Growth)
Name of representative:	Keita Mori, Representative Director and President
For inquiries, contact:	Yoshihiro Kakutani, Corporate Officer of Management Administration (Phone: 03-6264-3481)

**Notice Concerning the Grant of New Patent for Cell Therapy  
Using SB623 for Chronic Ischemic Stroke in the United States**

SanBio Co., Ltd. hereby provides on this matter as per the attached document.



October 30, 2024  
SanBio Co., Ltd.

## **Notice Concerning the Grant of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the United States**

SanBio Co., Ltd. (Head office: Tokyo, Representative Director and President: Keita Mori) and its subsidiary SanBio, Inc. announced on July 25, 2024 that the US Patent and Trademark Office has issued Notice of Allowance of the patent application SanBio, Inc. filed for its key development product SB623 (INN: vandefitemcel) for the treatment of chronic ischemic stroke. We announce that the patent was granted on October 22, 2024.

Details of the granted patent is as below.

Name of invention:	CELL THERAPIES AND METHODS OF TREATMENT FOR SMALL-VOLUME STROKE
Country of filing:	US
Patent number:	US 12,121,544
Date of patent acquisition:	October 22, 2024
Applicant:	SanBio, Inc. Mountain View, CA (US)*

\* Address is as of filing date. Currently SanBio, Inc. is located in Oakland, CA (US)

For more information on this patent, please refer to the press release dated July 25, 2024.

SanBio is focused on building and maintaining its patent portfolio as part of its efforts to maximize corporate value. The acquisition of the patent significantly will extend the term of the use patent for SB623 for the treatment of chronic ischemic stroke in the US, the largest market. SanBio will continue exploring ways to expand the indications of SB623 to include chronic ischemic stroke.

This matter will have only a minimal impact on the financial performance of the current fiscal year.

### **About Stroke**

Stroke is a condition caused by a blood clot blocking a blood vessel in the brain, leading to insufficient blood supply to brain cells. It is estimated that there are 6.85 million stroke patients in the US<sup>1</sup> and 1.19 million in Japan<sup>2</sup>. Early treatment and intervention are crucial, as severe disabilities may become permanent once the condition enters the chronic phase. Current treatments for stroke patients in the chronic phase include pharmacotherapy to prevent recurrence and rehabilitation. However, there are no drugs available that

fundamentally address and treat chronic motor function disorders caused by stroke, indicating a high unmet medical need.

### **About SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)**

SanBio was founded in California, the US in 2001 with the vision of becoming a global leader in the field of regenerative medicine, and is engaged in the regenerative cell business—we research, develop, manufacture, and sell regenerative cell medicines. On July 31st 2024, under the Sakigake Designation Program, we obtained conditional and time-limited approval for our mainstay product AKUUGO® for the indication of improving chronic motor paralysis associated with traumatic brain injury. Going forward, we will continue focusing our R&D efforts on central nervous system disorders with significant unmet medical needs that cannot be addressed by existing medicine or drugs. The Company is headquartered in Tokyo, Japan and Oakland, California, and additional information about SanBio Group is available at <https://sanbio.com/en/>

#### <References>

<sup>1</sup> Company analysis based on multiple sources

<sup>2</sup> The number of “Cerebral infarction” patients in *Patient Survey 2020*, the Ministry of Health, Labour and Welfare

#### [Disclaimer]

This document may contain forward-looking statements such as forecasts, outlooks, goals, and plans related to SunBio Inc. These statements are based on information available to the Company at the time of preparation of this document, including forecasts and other projections. In addition, certain assumptions (hypotheses) are used in making these statements. These statements or assumptions are subjective and may prove to be incorrect in the future or may not be realized in the future. There are several uncertainties and risks that could cause this to happen. Please refer to our financial statements and annual reports for additional information on these matters. The forward-looking statements in this document speak only as of the date of this document (or as otherwise indicated therein), as described above, and we have no obligation or policy to update such information from time to time to keep it current.

#### **For more information, contact:**

SanBio Co., Ltd.

Management Administration

Email: [info@sanbio.com](mailto:info@sanbio.com)